C-QYQINapa Therapeutics
NAD metabolism, AI drug discovery, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-QYQI
C-QYQIC-QYQINAD metabolism, AI drug discovery, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Napa Therapeutics NAD metabolism, AI drug discovery, small molecules
Napa Therapeutics, Ltd. is a biotechnology company formed by Juvenescence, The Buck Institute for Research on Aging, and Insilico Medicine. It is developing small molecule drugs against a novel target linked to one of the fundamental processes of aging. The company is based on research in NAD metabolism from Eric Verdin's lab and uses Insilico Medicine's drug development engine to accelerate compound discovery.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Napa Therapeutics — Early mechanism · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic